Analysis of miR-29 Serum Levels in Patients with Neuroendocrine Tumors-Results from an Exploratory Study.
biomarker
miR-29
neuroendocrine carcinoma
neuroendocrine tumor
survival
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
06 Sep 2020
06 Sep 2020
Historique:
received:
25
07
2020
revised:
30
08
2020
accepted:
03
09
2020
entrez:
9
9
2020
pubmed:
10
9
2020
medline:
10
9
2020
Statut:
epublish
Résumé
Due to its involvement in tumor biology as well as tumor-associated stroma cell responses, recent data suggested a potential role of miR-29 as a biomarker for different malignancies. However, its role in neuroendocrine tumors (NETs) is only poorly understood. We measured circulating levels of miR-29b in 45 patients with NET and compared them to 19 healthy controls. Results were correlated with clinical records. In our cohort of NET patients treated between 2010 and 2019 at our department, miR-29b serum levels were significantly downregulated when compared to healthy control samples. Further, a significant correlation between chromogranin A (CgA) and relative miR-29b levels was noted. However, serum levels of miR-29b were independent of tumor-related factors such as proliferation activity according to Ki-67 index, tumor grading, the TMN stage of malignant tumors, somatostatin receptor expression or clinical features such as functional or non-functional disease and presence of tumor relapse. Finally, in contrast to previous results from other malignancies, miR-29b serum levels were not a significant predictor of overall survival in NET patients. Our data suggest a role for miR-29b serum levels as a previously unrecognized biomarker for diagnosis of NET. However, miR-29 does not allow for predicting tumor stage or patients' outcome.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Due to its involvement in tumor biology as well as tumor-associated stroma cell responses, recent data suggested a potential role of miR-29 as a biomarker for different malignancies. However, its role in neuroendocrine tumors (NETs) is only poorly understood.
METHODS
METHODS
We measured circulating levels of miR-29b in 45 patients with NET and compared them to 19 healthy controls. Results were correlated with clinical records.
RESULTS
RESULTS
In our cohort of NET patients treated between 2010 and 2019 at our department, miR-29b serum levels were significantly downregulated when compared to healthy control samples. Further, a significant correlation between chromogranin A (CgA) and relative miR-29b levels was noted. However, serum levels of miR-29b were independent of tumor-related factors such as proliferation activity according to Ki-67 index, tumor grading, the TMN stage of malignant tumors, somatostatin receptor expression or clinical features such as functional or non-functional disease and presence of tumor relapse. Finally, in contrast to previous results from other malignancies, miR-29b serum levels were not a significant predictor of overall survival in NET patients.
CONCLUSION
CONCLUSIONS
Our data suggest a role for miR-29b serum levels as a previously unrecognized biomarker for diagnosis of NET. However, miR-29 does not allow for predicting tumor stage or patients' outcome.
Identifiants
pubmed: 32899973
pii: jcm9092881
doi: 10.3390/jcm9092881
pmc: PMC7565987
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : German Research Foundation
ID : DFG RO 4317/4-1
Organisme : German Center for Cardiovascular Diseases
ID : DZHK, B18-005Ext
Références
Oncotarget. 2017 Apr 7;8(33):54331-54344
pubmed: 28903345
Mod Pathol. 2014 Dec;27(12):1632-40
pubmed: 24875640
Hepatology. 2011 Jan;53(1):209-18
pubmed: 20890893
Expert Opin Biol Ther. 2009 Jun;9(6):703-711
pubmed: 19426115
Neuroendocrinology. 2018;106(1):47-57
pubmed: 28208131
Int J Mol Sci. 2018 Jan 16;19(1):
pubmed: 29337905
Acta Physiol (Oxf). 2017 Feb;219(2):346-361
pubmed: 27009502
PLoS One. 2012;7(3):e32999
pubmed: 22412969
J Hepatol. 2017 Mar;66(3):655-656
pubmed: 27702640
Gut. 2020 Apr;69(4):748-763
pubmed: 32034004
Nat Rev Endocrinol. 2018 Nov;14(11):656-669
pubmed: 30158549
J Cardiovasc Med (Hagerstown). 2015 Jul;16(7):480-90
pubmed: 25689084
Infect Genet Evol. 2019 Oct;74:103938
pubmed: 31242452
Cardiovasc Res. 2013 Oct 1;100(1):7-18
pubmed: 23774505
Bull Exp Biol Med. 2016 Mar;160(5):702-4
pubmed: 27021085
PLoS One. 2019 Jan 17;14(1):e0210944
pubmed: 30653586
J Cell Physiol. 2019 Nov;234(11):19280-19297
pubmed: 30950056
Ann Surg. 2019 Aug 1;:
pubmed: 31373926
Mol Med Rep. 2015 Jul;12(1):615-22
pubmed: 25738263
J Allergy Clin Immunol. 2018 Apr;141(4):1202-1207
pubmed: 29074454
Endocr Relat Cancer. 2018 Jan;25(1):R11-R29
pubmed: 29066503
World J Gastroenterol. 2016 Dec 7;22(45):9944-9953
pubmed: 28018101
PLoS One. 2013;8(1):e54612
pubmed: 23372743
Z Gastroenterol. 2018 Jun;56(6):583-681
pubmed: 29890561
Future Sci OA. 2020 Feb 26;6(4):FSO465
pubmed: 32257377
Microrna. 2018;7(3):215-222
pubmed: 29848284
Digestion. 2017;95(2):109-114
pubmed: 28161703
Nat Rev Clin Oncol. 2019 Mar;16(3):149-150
pubmed: 30390038
Med Oncol. 2014 Aug;31(8):37
pubmed: 25015394
Neuroendocrinology. 2019;108(1):26-36
pubmed: 30282083
Arch Intern Med. 2011 Aug 8;171(15):1322-31
pubmed: 21824946
Mol Ther Oncolytics. 2018 Dec 31;12:173-194
pubmed: 30788428
Cell Physiol Biochem. 2018;50(1):385-397
pubmed: 30286469